Companies · Biotech
New York City · NY, USA · Biotech · founded 2025 · https://www.photoniumoptics.com/
Diligence memoA one-page analyst read on Photonium — recommendation, valuation, rhythm, risks.→Photonium: limited disclosed financing to assess.
Synthesized from the figures below est. — every claim rests on a number shown on this page.
Photonium is one of 233 Biotech companies tracked from New York City, NY, USA, on record since 2025. By capital raised it ranks mid-pack (ahead of 67% of sector peers), and mid-pack by modeled valuation est..
Ranking is computed against this company's own sector cohort — reported capital is fact; valuation tiers are modeled.
AI analyst read est. — model-extracted from this company's public description, not a verified fact. 30%
operates a technology-led product inferred from public copy
Grounded in: “You are a venture analyst”
AI-Powered Optical Consulting & Software
Photonium is building software to automate optical system design. We supercharge optics experts with intelligent tooling to reduce costs and deliver faster. We handle the full design stack — from optimization, verification, sourcing, to prototyping — for AR/VR, quantum, biotech, metrology/chip fab, LiDAR, and more.
As reported in public records reported — not modeled.
Solid bars are reported offering amounts reported; hatched bars are the modeled post-money valuation est. — both on one shared scale so you can read raise-vs-worth at each round directly. Use the toggles to overlay data labels and the niche-peer / market average value lines.
No round amounts on record to chart.
No staged rounds to sequence.
Round size and date are reported; the stage label is inferred from round size. Valuation is modeled from stage benchmarks. Directional, not a quoted figure.
Not enough modeled valuation points to chart a trajectory.
Benchmarked against 233 companies in Biotech. Each bar is a median (the middle company, not an average — outliers don't skew it). Two yardsticks: real money raised (reported on Form D) and modeled value (our estimate est.). These are whole-sector medians across all stages, except the per-stage row.
Raised more than 67% of sector peers (real $). Modeled value above 67% of peers (estimate).
Stage is inferred from round size est., not reported on the filing — a round's dollar size maps to a bucket: Pre-Seed <$1.0M · Seed $1.0M–$4.0M · Series A $4.0M–$15M · Series B $15M–$40M · Series C $40M–$100M · Series D+ $100M–$400M · Growth/Late >$400M.
| Stage | Amount · real | Announced | Post-money · est | Value · est | Conf. |
|---|---|---|---|---|---|
| No rounds recorded. | |||||
Predictive signals are modeled est. from this company's own cadence and step-up, plus sector benchmarks — directional, not advice. Peer set and a CSV export live in your analyst workspace.
Photonium is an official record sourced from the U.S. Securities and Exchange Commission (SEC). U.S. data is aggregated from SEC Form D filings.
Nearest neighbours across the whole database — matched on sector, stage and capital scale, and on shared operators (officers or directors named at both companies in public filings). A discovery shortlist, not a valuation cohort — verify before acting, the same way modeled figures are directional.
| Company | Sector | Stage | Raised · real | Value · est | Why similar |
|---|---|---|---|---|---|
| 10x Science | Biotech | — | — | — | same sector |
| 1849 bio | Biotech | — | — | — | same sector |
| 1910 | Biotech | — | — | — | same sector |
| 20n | Biotech | — | — | — | same sector |
| 54Gene, Inc. | Biotech | Series B | $48.3M | $598.4M | same sector |
| Abacus Bioscience Inc. | Biotech | Series A | $4.4M | $46.6M | same sector |
| Abalone Bio | Biotech | — | — | — | same sector |
| Acoustic Wave Cell Therapy, Inc. | Biotech | Series A | $20.5M | $84.9M | same sector |
Matched by meaning, not labels — a local language model reads each company's name, sector and description and ranks the closest in that learned space. This catches look-alikes that cross sector boundaries; the structured list above explains its matches, this one trusts the text. Directional, like every modeled signal here.
| Company | Sector | Stage | Value · est | Match |
|---|---|---|---|---|
| Optherium Labs OU | Software / Tech | Series D+ | $7.4B | 76% |
| Lambda Lab Corp. | Software / Tech | Pre-Seed | $29.7M | 75% |
| Allium Labs, Inc. | Software / Tech | Series A | $52.5M | 74% |
| Osium AI Speed up materials innovation with Artificial Intelligence | Climate / Cleantech | — | — | 74% |
| Photon Interactive UK Ltd | Other Technology | Series B | $454.3M | 73% |
| OpticSurg Inc. | Biotechnology | Pre-Seed | $13.8M | 73% |
| Gridium Inc. | Other Technology | Seed | $23.3M | 73% |
| Quantinium, Inc. | Other Technology | Seed | $23.4M | 72% |
See where Photonium sits in the wider market — its sector, location and stage cohorts, each with their own leaderboards and capital-flow timelines.
If you work at Photonium, claim this profile or suggest a correction. We aggregate from public filings, so help us keep your description, website and links accurate.
Is this your company? Update your profile or add contact details — and choose exactly who can reach you. Reviewed before anything is published.